pentapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
=== Immune system === BaP has an effect on the number of white blood cells, inhibiting some of them from differentiating into macrophages, the body's first line of defense to fight infections. In 2016, the molecular mechanism was uncovered as damage to the macrophage membrane's lipid raft integrity by decreasing membrane cholesterol at 25%. This means less immunoreceptors CD32 (a member of the Fc family of immunoreceptors) could bind to IgG and turn the white blood cell into a macrophage. Therefore, macrophage membranes become susceptible to bacterial infections.
exocytosis Any active transport process by which a substance is secreted from or transported out of a cell, crossing the plasma membrane from the interior of the cell into the extracellular space, especially that which occurs by the fusion of the membrane surrounding a secretory vesicle with the larger cell membrane. This fusion causes the intra-vesicular space to merge with the extracellular fluid, releasing the vesicle's contents on the exterior side of the cell without exposing them to the hydrophobic space between the lipid bilayer. More narrowly the term may refer in particular to the bulk transport of a large amount of molecules out of the cell all at once, often metabolites or hormones which are too large and polar to passively diffuse across the membrane themselves. The reverse process, whereby materials are invaginated into the cell, is known as endocytosis.
==== Gene expression ==== Studies have shown that morphine can alter the expression of several genes. A single injection of morphine has been shown to alter the expression of two major groups of genes, for proteins involved in mitochondrial respiration and for cytoskeleton-related proteins.
Sources: en.wikipedia.org
=== As a toxin conjugation agent === Glycine conjugation pathway has not been fully investigated. Glycine is thought to be a hepatic detoxifier of a number of endogenous and xenobiotic organic acids. Bile acids are normally conjugated to glycine in order to increase their solubility in water. The human body rapidly clears sodium benzoate by combining it with glycine to form hippuric acid which is then excreted. The metabolic pathway for this begins with the conversion of benzoate by butyrate-CoA ligase into an intermediate product, benzoyl-CoA, which is then metabolized by glycine N-acyltransferase into hippuric acid.
Autologous cultured chondrocytes on porcine collagen membrane (Maci) is a treatment to correct cartilage defects in the knee. It is used to treat symptomatic, full-thickness cartilage defects of the knee with or without bone involvement. Autologous cultured chondrocytes on porcine collagen membrane is an autologous cellularized scaffold product. This treatment is approved by the US Food and Drug Administration (FDA). It is only administered to adults. Healthy cartilage is removed from the person's own knees and a 'scaffold' is created on which the healthy tissue growths. This is an autologous matrix-induced chondrogenesis procedure which prevents tissue rejection complications since the transplanted cartilage comes from the same person. Autologous cultured chondrocytes on porcine collagen membrane was approved for use in the United States in May 2019.
=== RNA === In recent years, the biological function of triplex RNA has become more studied. Some roles include increasing stability, translation, influencing ligand binding, and catalysis. One example of ligand binding being influenced by a triple helix is in the SAM-II riboswitch where the triple helix creates a binding site that will uniquely accept S-adenosylmethionine (SAM). The ribonucleoprotein complex telomerase, responsible for replicating the tail-ends of DNA (telomeres) also contains triplex RNA believed to be necessary for proper telomerase functioning. The triple helix at the 3' end of the PAN and MALAT1 long-noncoding RNAs serves to stabilize the RNA by protecting the Poly(A) tail from deadenylation, which subsequently affect their functions in viral pathogenesis and multiple human cancers. Additionally, RNA triple helices can stabilize mRNAs by formation of a poly(A) tail 3'-end binding pocket.
Sources: en.wikipedia.org
Watanabe et al. (2026) report evidence from the study of genomes of the Jōmon people indicative of their descent from Upper Paleolithic continental East Asian populations that settled the Japanese archipelago between 27,000 and 19,000 years ago, and evidence of cold adaptation in the Jōmon lineage. Evidence from the study of stone tool assemblages from the Buhais Rockshelter (United Arab Emirates) indicative of repeated occupation of the studied area between 210,000 and 16,000 years ago (including in the time of overall increased aridity of the Arabian Peninsula between 60,000 and 16,000 years ago) is presented by Bretzke et al. (2026). Evidence from the study of Natufian artefacts and rock art from the Sahout site and the neighbouring sites of Jebel Arnaan and Jebel Misma (Saudi Arabia), indicative of occupation of the studied area by communities interacting with people from the Fertile Crescent during the terminal Pleistocene and early Holocene, is presented by Shipton et al. (2026). Davin et al. (2026) report the discovery of clay ornaments from Natufian (late Epipalaeolithic) sites in Israel, interpreted as produced both by adults and by children, and representing the earliest known clay ornamental tradition outside of Europe. Evidence of importance of consumption of lizards and snakes in subsistence strategies of Natufian foragers from the El Wad site (Israel) is presented by Lev, Weinstein-Evron & Yeshurun (2026).
The genus Oenococcus has one main member involved in winemaking, O. oeni, once known as Leuconostoc oeni. Despite having the name Oenococcus, under the microscope, the bacterium has a bacillus (shape) rod shape. The bacteria is a Gram-positive, facultative anaerobe that can utilize some oxygen for aerobic respiration but usually produces cellular energy through fermentation. O. oeni is a heterofermenter that creates multiple end products from the use of glucose with D-lactic acid and carbon dioxide being produced in roughly equal amounts to either ethanol or acetate. In reductive conditions (such as near the end of alcoholic fermentation), the third end product is usually ethanol while in slightly oxidative (such as early in alcohol fermentation or in an untopped barrel), the bacteria are more likely to produce acetate. Some O. oeni strains can use fructose to create mannitol (which can lead to wine fault known as mannitol taint), while many other strains can break down the amino acid arginine (which can be present in the wine that is resting on the lees after fermentation from the autolysis of dead yeast cells) into ammonia. In addition to the hexose glucose and fructose sugars, most strains of O. oeni can use the residual pentose sugars left behind from yeast fermentation including L-arabinose and ribose. Only around 45% of O. oeni strains can ferment sucrose (the form of sugar usually added for chaptalization that gets converted by yeast into glucose and fructose). Winemakers tend to prefer O. oeni for several reasons.
== Design and manufacture == The design and manufacture of PMPs involves biomaterial selection, nanoparticle engineering, surface functionalization, and scalable production techniques to mimic the structure, function, and biomechanical properties of native platelets. One such design is a nanohair decorated microsphere made by a research group. These are small particles created from a combination of polystyrene, polyaniline (PANi), and epithelial cell adhesion molecule (EpCAM) antibodies that bind to circulating tumor cells. These spheres are designed to have a 1μm diameter created with the polystyrene molecules where the inner layer is hydrophilic to surround the core. The PANi is used to create nanohairs that simulate the natural aggregation of platelets. These nanohairs are attached to the surface of the polystyrene nanoparticles and range in length from 100 to 800 nm. The EpCAM antibodies are also attached to the nanospheres and are capable of binding to the EpCAM of circulating tumor cells in order to capture and remove them from circulation.
== External links == "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks". U.S. Food and Drug Administration (FDA). 7 January 2021. Archived from the original on 14 September 2019.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.